LivaNova (LIVN) Q2 2026 earnings review
Core Segments Surge as Critical Supply Bottleneck is Solved
LivaNova delivered a robust Q2 2026, accelerating top-line growth to 10.8% YoY ($390.6M) and prompting a full-year revenue and adjusted EPS guidance raise. The standout operational win was a long-term agreement with Thermo Fisher Scientific, directly addressing the third-party oxygenator supply constraints that plagued the company in previous quarters. Both Cardiopulmonary and Neuromodulation segments achieved double-digit growth. While GAAP Net Income exploded by 299% to $108.6M, this was heavily skewed by a one-time $95.4M Italian tax benefit related to the SNIA environmental liability. Core operations remain healthy, though management lowered Free Cash Flow guidance to fund necessary capacity expansion.
🐂 Bull Case
The Thermo Fisher agreement solves the primary limiting factor for Cardiopulmonary growth. LivaNova can now aggressively pursue oxygenator market share (already up to ~40%) without third-party component bottlenecks.
Neuromodulation revenue growth accelerated to 10.1%, up from mid-single digits in FY25, heavily benefiting from the ~48% Medicare reimbursement increase and strong CORE VNS clinical data adoption.
🐻 Bear Case
Full-year Adjusted Free Cash Flow guidance was lowered by $20M at the midpoint. Increased strategic investments in capacity expansion and IT infrastructure are weighing on cash conversion in the near term.
GAAP profitability was heavily artificially inflated by a $95.4M Italian tax benefit. Without this discrete item, GAAP operating income actually declined YoY from $54.2M to $49.5M.
⚖️ Verdict: 🟢
Bullish. The strategic resolution of the oxygenator supply constraint via Thermo Fisher removes the largest overhang on the stock. Paired with strong reimbursement tailwinds in Epilepsy and an impending OSA launch, the core growth engine is highly durable.
Key Themes
Thermo Fisher Partnership Unlocks Oxygenator Capacity
In previous quarters, management repeatedly cited third-party component supply as the singular bottleneck preventing faster Cardiopulmonary expansion, despite robust market demand. The new long-term agreement with Thermo Fisher Scientific specifically targets critical oxygenator components. This is a massive strategic win that supports LivaNova's goal to increase oxygenator capacity by 60% by 2030 and capture further market share.
Neuromodulation Reaches Double-Digit Growth
The Neuromodulation segment successfully broke out of its historical mid-single-digit growth trajectory, accelerating to 10.1% YoY ($166.9M). This validates the narrative established in Q1: the ~48% Medicare reimbursement increase for new implants is fundamentally improving hospital economics, driving immediate realized price gains and expanding the patient funnel.
OSA Pipeline Validated by PolySync Data
LivaNova continues to de-risk its Obstructive Sleep Apnea (OSA) commercial launch planned for 2027. The company announced that its PolySync programming algorithm increased the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in patients with moderate to severe OSA. This directly combats previous concerns about non-responder rates and establishes a strong clinical value proposition against established competitors.
Capital Intensity Pressuring Free Cash Flow
Management lowered FY26 Adjusted Free Cash Flow guidance to $140M-$160M (down from $160M-$180M). This deceleration in cash conversion is entirely driven by strategic CapEx—investing in Cardiopulmonary capacity (new manufacturing lines) and IT infrastructure. While structurally positive for long-term growth, it pushes out the timeline for hitting the company's 80% long-term cash conversion target.
GAAP Profitability Masked by SNIA Tax Benefit
Investors must strictly look at adjusted metrics this quarter. GAAP Net Income jumped to $108.6M (vs $27.2M a year ago), but this was almost entirely fueled by an €81.8M ($95.4M) discrete tax benefit from the Italian tax authority regarding the deductibility of the legacy SNIA environmental liability. Excluding this, GAAP Operating Income actually declined to $49.5M from $54.2M due to higher COGS and operating expenses.
Macro Pressures: Tariffs and Geopolitics
While overshadowed by the top-line beat, the macro environment remains a headwind. In Q1, management cited a combined ~$10M hit from Middle East conflict logistics and net tariffs. Operating expenses remain elevated, with SG&A increasing 14.7% YoY, indicating that supply chain execution is still requiring heavy lifting despite the Thermo Fisher agreement.
Other KPIs
Accelerating. Up 130 basis points from 21.9% in 25Q2. The expansion was driven by fixed-cost leverage on higher sales volumes, which offset increases in R&D investments required for the OSA commercialization ramp.
Accelerating. European Cardiopulmonary sales surged 26.3% YoY, vastly outperforming the U.S. (+2.2%). This highlights immense regional traction for the Essenz Perfusion System upgrade cycle and strong realized pricing dynamics.
Stable. Up slightly from $62.9M in 25Q2, though H1 total operating cash flow ($81.8M) is trailing H1 2025 ($86.9M). This reflects heavier working capital requirements to support the double-digit sales growth.
Guidance
Accelerating. Raised by 100 basis points from the prior 7% to 8% range. Foreign currency is expected to provide an additional ~1% tailwind, pushing reported growth expectations closer to 9-10%.
Accelerating. Raised by $0.10 at the midpoint from the prior $4.20 to $4.30 range. Implies ~11.5% YoY growth over FY25's $3.90, demonstrating strong flow-through from the revenue beat despite higher planned investments.
Decelerating. Lowered from the previous $160M to $180M range. The company explicitly attributed the $20M midpoint reduction to required capital expenditures for CP capacity expansion, innovation, and IT infrastructure. This indicates a near-term margin/cash trade-off for long-term supply security.
Key Questions
Thermo Fisher Integration Timeline
How quickly will the new Thermo Fisher agreement impact actual manufacturing output? Will this primarily support the new oxygenator manufacturing line slated for H2 2026, or does it also benefit existing capacity immediately?
CapEx Normalization
With the reduction in the Free Cash Flow guide due to capacity expansion and IT infrastructure, what is the expected normalized run-rate for CapEx in 2027 and 2028?
OSA Commercial Spend
As the PolySync data comes in strong and the 2027 launch approaches, how should we model the incremental commercial SG&A build-out in the second half of 2026 to prep the sales force?
U.S. vs Europe CP Disconnect
U.S. Cardiopulmonary growth was relatively soft at 2.2% compared to Europe's 26.3%. Is this purely a timing issue regarding Essenz capital placements, or is there a differing competitive dynamic in the U.S. consumables market?